PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
April 30, 2026CancersOpen Access

CRLF1 Drives Prostate Cancer Progression via COMP-Mediated Activation of the FAK/PI3K/AKT Signaling Pathway

View Full Paper
Ask AI
Bookmark
Share

Authors

ZLZhongze LiJWJinrun WangLXLizhe Xu

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates CRLF1's role in prostate cancer progression, suggesting a new therapeutic target.

Key Points

  • The investigation aimed to clarify the role and mechanisms of CRLF1 in prostate cancer progression.
  • Conducted bioinformatics analyses using TCGA-PRAD dataset
  • Validated CRLF1 and COMP levels through qRT-PCR and Western blot
  • Performed in vitro functional assessments and utilized a xenograft tumor model for in vivo validation.
  • CRLF1 and COMP levels were significantly higher in prostate cancer tissues compared to benign tissues.
  • Silencing CRLF1 reduced cancer cell growth and invasion, and increased apoptosis.
  • CRLF1 activates the FAK/PI3K/AKT signaling pathway through COMP to promote tumor progression.

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/69f2f1771e5f7920c638726ehttps://doi.org/10.3390/cancers18091395
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prostate Cancer Among Black Men in Canada2024 · 11 citations
  2. 2Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone2025 · 6 citations
  3. 32022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review2023 · 847 citations
  4. 4Therapy resistance in prostate cancer: mechanism, signaling and reversal strategies2024 · 19 citations
  5. 5Cross-Species Functional Analysis of Cancer-Associated Fibroblasts Identifies a Critical Role for CLCF1 and IL-6 in Non–Small Cell Lung Cancer In Vivo2012 · 128 citations